Richard J Lee
Affiliations: | 2000 | Albert Einstein College of Medicine of Yeshiva University, NY, United States |
Google:
"Richard Lee"Parents
Sign in to add mentor| Richard Pestell | grad student | 2000 | Albert Einstein College of Medicine of Yeshiva University |
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Miyamoto DT, Lee RJ. (2020) PIK Carefully, AKT Accordingly: Towards Precision Medicine in Prostate Cancer. European Urology |
| Naeem A, Dakshanamurthy S, Walthieu H, et al. (2020) Predicting new drug indications for prostate cancer: The integration of an in silico proteochemometric network pharmacology platform with patient-derived primary prostate cells. The Prostate |
| Meric-Bernstam F, Lee RJ, Carthon BC, et al. (2019) CB-839, a glutaminase inhibitor, in combination with cabozantinib in patients with clear cell and papillary metastatic renal cell cancer (mRCC): Results of a phase I study. Journal of Clinical Oncology. 37: 549-549 |
| Hwang W, Pleskow H, Czapla JAA, et al. (2019) Integrated Gene Expression Score in Circulating Tumor Cells to Predict Treatment Response in Muscle-Invasive Bladder Cancer International Journal of Radiation Oncology*Biology*Physics. 105: E663 |
| Tricoli L, Naeem A, Parasido E, et al. (2018) Characterization of the effects of defined, multidimensional culture conditions on conditionally reprogrammed primary human prostate cells. Oncotarget. 9: 2193-2207 |
| Miyamoto DT, Lee RJ, Kalinich M, et al. (2018) An RNA-based digital circulating tumor cell signature is predictive of drug response and early dissemination in prostate cancer. Cancer Discovery |
| Tannir NM, Fan AC, Lee RJ, et al. (2018) Phase 1 study of glutaminase (GLS) inhibitor CB-839 combined with either everolimus (E) or cabozantinib (Cabo) in patients (pts) with clear cell (cc) and papillary (pap) metastatic renal cell cancer (mRCC). Journal of Clinical Oncology. 36: 603-603 |
| Luo J, Attard G, Balk SP, et al. (2017) Role of Androgen Receptor Variants in Prostate Cancer: Report from the 2017 Mission Androgen Receptor Variants Meeting. European Urology |
| Zheng Y, Miyamoto DT, Wittner BS, et al. (2017) Expression of β-globin by cancer cells promotes cell survival during blood-borne dissemination. Nature Communications. 8: 14344 |
| Dewal N, He Y, Lee RJ, et al. (2017) Abstract 3394: CGP identifies largely non-overlapping high tumor mutational burden and HRD genomic alterations in 721 clinically advanced prostate acinar adenocarcinoma cases Cancer Research. 77: 3394-3394 |